What we do
Alliance Medical Group produces and supplies registered radiopharmaceuticals and investigational medicinal products (IMPDs) to support PET and nuclear medicine services across the UK and Northern Europe.
Alliance Medical Group produces and supplies registered radiopharmaceuticals and investigational medicinal products (IMPDs) to support PET and nuclear medicine services across the UK and Northern Europe.
Our radiopharmacy solutions are built around short half‑life tracers, fixed clinical schedules and strict regulatory requirements.
From facilities across the UK and Northern Europe, we supply radiopharmaceuticals to countries including Sweden, Finland, the Baltic states, Poland, Germany, Austria, the Netherlands and Serbia, with the capability to support wider European delivery.
The operational realities of radiopharmacy define what we do: in‑house production, narrow delivery windows, regulatory oversight and close alignment with imaging pathways.
Alliance Medical Group supplies radiopharmaceuticals to advanced diagnostic services across Northern Europe, supporting PET and nuclear medicine pathways where proximity, timing and regulatory alignment are critical.
Our Northern European arm enables consistent diagnostic delivery across multiple health systems without compromising regulatory, quality or timing requirements.
In the UK, Alliance Medical operates the country’s largest network of licensed radiopharmaceutical production units, supporting PET imaging services across England, Scotland and Wales.
This national infrastructure plays a critical role in supporting PET‑CT delivery across the UK health system.
Radiopharmaceutical manufacturing follows a tightly controlled, time‑critical process designed to ensure safety, quality and regulatory compliance at every stage.
View our products
Radioisotopes are produced in‑house using cyclotrons, timed precisely to support clinical and research demand.
Isotopes are synthesised into radiopharmaceutical tracers within controlled clean‑room environments using fixed, optimised processes.
Finished products are dispensed aseptically within shielded hot‑cells under Grade A clean‑room conditions.
Prepared vials are sealed into compliant transport containers in line with ADR and regulatory requirements.
Each batch undergoes immediate in‑house testing to confirm safety, purity and compliance.
Products are transported via specialist, compliant logistics using the fastest available routes.
A Qualified Person (QP) performs a final review before releasing the product for clinical or research use.
Delivering diagnostics
and insight at scale
